Indaptus Therapeutics 3Q 2026: EPS ($0.01) — 10-Q Summary

Indaptus Therapeutics reported a 65% narrower net loss YoY for 3Q 2026, with expenses falling due to reduced clinical activity and payroll costs. R&D expenses dropped 82% to $271,204, while G&A expenses declined 24% to $864,663. The company discontinued further enrollment in its Decoy20 study and began a new research collaboration with Kunming University of Science and Technology.

Original reporting
Published Nov 13, 2026, 1:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Indaptus Therapeutics 3Q 2026: EPS ($0.01) — 10-Q Summary — source image
Decision brief

The 30-second read

$INDPNeutralMed
01

Why it matters

The disclosed financial improvements may prompt short‑term price appreciation, but ongoing clinical uncertainty tempers upside.

02

Market read

First‑time quarterly data for a micro‑cap biotech; relevance primarily to sector‑focused traders.

03

What to watch

Potential upcoming clinical trial setbacks or funding needs could offset short‑term cost improvements.

Relevance 6/10Novelty 7/10Timing: after-hours release

Background

Indaptus Therapeutics filed its Q3 2026 10‑Q, highlighting a narrowed net loss and discontinued clinical enrollment.

Company-level read

Ticker impact

$INDPNeutralHigh confidence
Context

10-Q filing shows net loss narrowed 65% YoY and EPS improved to -$0.01, the first report of these quarterly results.

Expected impact

potential modest upside as the market prices in the narrowed loss and expense cuts

Evidence & confidence

The company still reports a loss, but the sharp decline in expenses and loss improvement are new data that can shift sentiment.

Market effects

Biotech peers may be re‑rated as cost‑control becomes a focus.

U.S. small‑cap biotech segment could see slight positive pressure.

Limited to investors tracking early‑stage biotech earnings.

Counterpoint

The loss remains material; investors may stay cautious despite expense cuts.

Key entities

  • Indaptus Therapeutics, Inc.

    U.S. listed biotech (ticker INDP) reporting Q3 2026 results.

Related articles

$INDPMed

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

$INDPMed

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.